Cargando…

Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States

Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United Stat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemmon, Christopher A., Zhou, Jie, Hobbs, Brian, Pennell, Nathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928881/ https://www.ncbi.nlm.nih.gov/pubmed/36634300 http://dx.doi.org/10.1200/PO.22.00294

Ejemplares similares

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
por: Criss, Steven D., et al.
Publicado: (2019)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
por: Hess, Lisa M., et al.
Publicado: (2022)

Next-Generation in Situ Hybridization Chain Reaction: Higher Gain, Lower Cost, Greater Durability
por: Choi, Harry M. T., et al.
Publicado: (2014)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hayashi, Hidetoshi, et al.
Publicado: (2011)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
por: Taipale, Kaisa, et al.
Publicado: (2017)

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study
por: Estevinho, Fernanda, et al.
Publicado: (2012)

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
por: Casadevall, David, et al.
Publicado: (2015)

Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
por: Shih, Jin-Yuan, et al.
Publicado: (2020)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer
por: Lu, Shun, et al.
Publicado: (2022)

Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma
por: Ma, Lin, et al.
Publicado: (2019)

Costs of Next-Generation Sequencing Assays in Non-Small Cell Lung Cancer: A Micro-Costing Study
por: Kumar, Srishti, et al.
Publicado: (2022)

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
por: Brooks, Gabriel A., et al.
Publicado: (2018)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Transcriptomic analysis of preovipositional embryonic arrest in a nonsquamate reptile (Chelonia mydas)
por: Gárriz, Angela, et al.
Publicado: (2022)

Recent insights into the tick microbiome gained through next-generation sequencing
por: Greay, Telleasha L., et al.
Publicado: (2018)

‘Next-generation’ genome wide association studies
por: Hopper, J, et al.
Publicado: (2012)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
por: Rahimi, Siavash, et al.
Publicado: (2017)

Next-generation phenomics for the Tree of Life
por: Burleigh, J. Gordon, et al.
Publicado: (2013)

The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Yue, et al.
Publicado: (2021)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity
por: Ikawa, Hiroaki, et al.
Publicado: (2019)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer
por: Wang, Siying, et al.
Publicado: (2013)

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
por: Yang, James Chin-Hsin, et al.
Publicado: (2015)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
por: Song, Xinyu, et al.
Publicado: (2018)

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer
por: Nakao, Akira, et al.
Publicado: (2022)

Microfluidics for genome-wide studies involving next generation sequencing
por: Ma, Sai, et al.
Publicado: (2017)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7jn2s3e09q85nj92ptdeoremsk